In vitro activity of iclaprim and comparator agents against Listeria monocytogenes clinical isolates from 2012 to 2018

Autor: Michael D. Huband, Leonard R. Duncan, Robert K. Flamm, Paul R. Rhomberg, David B. Huang, Yahse K. Edah
Rok vydání: 2021
Předmět:
Zdroj: Journal of Global Antimicrobial Resistance, Vol 25, Iss, Pp 14-17 (2021)
ISSN: 2213-7165
DOI: 10.1016/j.jgar.2021.02.015
Popis: Objective This study examined the in vitro activity of iclaprim and comparators against 40 Listeria monocytogenes clinical isolates mostly (95%) from patients with bloodstream infections (BSI) from the United States, Australia/New Zealand, Latin America, and Europe collected between 2012-2018 were tested. Methods Susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) interpretations were based on CLSI criteria. Results The iclaprim MIC90 value for all L. monocytogenes was 0.015 µg/ml. The MIC50/90 values for iclaprim were 4-fold lower than trimethoprim, the only FDA approved dihydrofolate reductase inhibitor, against all L. monocytogenes. Conclusions Iclaprim demonstrated lower MIC values than trimethoprim against a collection (2012-2018) of L. monocytogenes clinical isolates mostly from patients with blood stream infections from the United States, Australia/New Zealand, Latin America, and Europe.
Databáze: OpenAIRE